CN113906017A - 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用 - Google Patents

作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用 Download PDF

Info

Publication number
CN113906017A
CN113906017A CN202080041488.6A CN202080041488A CN113906017A CN 113906017 A CN113906017 A CN 113906017A CN 202080041488 A CN202080041488 A CN 202080041488A CN 113906017 A CN113906017 A CN 113906017A
Authority
CN
China
Prior art keywords
compound
isomer
pharmaceutically acceptable
acceptable salt
calculated value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080041488.6A
Other languages
English (en)
Inventor
刘奕志
王延东
吴凌云
尤旭
肖哲明
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Runer Eye Medicine Guangzhou Co ltd
Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Original Assignee
Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd filed Critical Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Publication of CN113906017A publication Critical patent/CN113906017A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一系列作为ROCK蛋白激酶抑制剂的异喹啉酮衍生物，及其在制备ROCK蛋白激酶抑制剂相关青光眼或高眼压症疾病的药物中的应用。具体公开了式(I)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN202080041488.6A 2019-06-21 2020-06-22 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用 Pending CN113906017A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910544202 2019-06-21
CN2019105442025 2019-06-21
CN201911078066 2019-11-06
CN2019110780661 2019-11-06
PCT/CN2020/097503 WO2020253882A1 (zh) 2019-06-21 2020-06-22 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用

Publications (1)

Publication Number Publication Date
CN113906017A true CN113906017A (zh) 2022-01-07

Family

ID=74040659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080041488.6A Pending CN113906017A (zh) 2019-06-21 2020-06-22 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用

Country Status (10)

Country Link
US (1) US20230024516A1 (zh)
EP (1) EP3988544A4 (zh)
JP (1) JP7398137B2 (zh)
KR (1) KR20220024868A (zh)
CN (1) CN113906017A (zh)
AU (1) AU2020296050B2 (zh)
CA (1) CA3144211A1 (zh)
MX (1) MX2021016068A (zh)
WO (1) WO2020253882A1 (zh)
ZA (1) ZA202200834B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114644618A (zh) * 2020-12-21 2022-06-21 广州润尔眼科生物科技有限公司 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
JP2006290827A (ja) * 2005-04-13 2006-10-26 Kowa Co 緑内障予防又は治療剤
EP1818329A1 (en) * 2004-11-29 2007-08-15 Kowa Company, Ltd. (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate
CN101253166A (zh) * 2005-08-30 2008-08-27 旭化成制药株式会社 磺酰胺化合物
CN101622243A (zh) * 2007-02-28 2010-01-06 旭化成制药株式会社 磺酰胺衍生物
CN103534249A (zh) * 2011-04-29 2014-01-22 阿玛克姆股份有限公司 新的rock抑制剂
CN105085525A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物
CN105085478A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JP3906284B2 (ja) 1995-04-14 2007-04-18 株式会社東芝 光ディスクからビデオ及びオーディオを再生する再生システム、その再生方法及び光ディスクの記録方法
JP4831826B2 (ja) 2006-10-23 2011-12-07 日本プラスト株式会社 ベンチレータ及びベンチレータ装置
EP3138843B1 (en) 2014-04-28 2019-11-27 Medshine Discovery Inc. Isoquinolinesulfonyl derivative as rho kinase inhibitor
CN114644618A (zh) * 2020-12-21 2022-06-21 广州润尔眼科生物科技有限公司 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
EP1818329A1 (en) * 2004-11-29 2007-08-15 Kowa Company, Ltd. (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate
JP2006290827A (ja) * 2005-04-13 2006-10-26 Kowa Co 緑内障予防又は治療剤
CN101253166A (zh) * 2005-08-30 2008-08-27 旭化成制药株式会社 磺酰胺化合物
CN101622243A (zh) * 2007-02-28 2010-01-06 旭化成制药株式会社 磺酰胺衍生物
CN103534249A (zh) * 2011-04-29 2014-01-22 阿玛克姆股份有限公司 新的rock抑制剂
CN105085525A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物
CN105085478A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途

Also Published As

Publication number Publication date
ZA202200834B (en) 2022-10-26
EP3988544A1 (en) 2022-04-27
WO2020253882A1 (zh) 2020-12-24
JP7398137B2 (ja) 2023-12-14
CA3144211A1 (en) 2020-12-24
KR20220024868A (ko) 2022-03-03
MX2021016068A (es) 2022-04-20
AU2020296050A1 (en) 2022-02-03
JP2022538086A (ja) 2022-08-31
AU2020296050B2 (en) 2023-04-06
US20230024516A1 (en) 2023-01-26
EP3988544A4 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
EP3536698B1 (en) Lanosterol prodrug compound and use thereof
CN103562186B (zh) 作为toll样受体调节剂的取代的苯并氮杂卓
CN103402996B (zh) 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
CN110234646A (zh) 靶向PROTAC的Tau蛋白及相关使用方法
CN105579444A (zh) 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途
KR20200135846A (ko) 인자 XIIa 억제제
CN104144922B (zh) 作为ep2受体拮抗剂的2h-吲唑
CN102448958A (zh) 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途
CN105492429A (zh) Sumo活化酶的杂芳基抑制剂
CA3230071A1 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110382479A (zh) 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
WO2015043364A1 (zh) 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN113906017A (zh) 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN105980381A (zh) 取代的尿嘧啶及其用途
CN116917277A (zh) 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法
CN107207476A (zh) 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途
CN103420981A (zh) 含有取代吡咯烷基的硫代吗啉类化合物
JP2020536922A (ja) 眼疾患を治療するためのアザビシクロ及びジアゼピン誘導体
JP7245397B2 (ja) 複素環化合物
WO2020216240A1 (zh) 用作血浆激肽释放酶抑制剂的双环烷类化合物
CN107614501A (zh) 羟基嘌呤类化合物及其应用
TWI690529B (zh) 羥基嘌呤類化合物及其應用
CN115677830A (zh) 肽酰胺类化合物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231205

Address after: 511400 Room 402, No. 223, Huanshi Avenue West, Nansha District, Guangzhou, Guangdong

Applicant after: Guangzhou runer eye Biotechnology Co.,Ltd.

Applicant after: Runer Eye Medicine (Guangzhou) Co.,Ltd.

Address before: 510630 room 1108, No. 100, Huangpu Avenue West, Tianhe District, Guangzhou City, Guangdong Province (office only)

Applicant before: Guangzhou runer eye Biotechnology Co.,Ltd.

TA01 Transfer of patent application right